Arne Holstein

Quantitative Analysis of Response to Treatment with Erlotinib in Advanced Non–Small Cell Lung Cancer Using ¹⁸F-FDG and 3′-Deoxy-3′-¹⁸F-Fluorothymidine PET

Deniz Kahraman, Matthias Scheffler, Thomas Zander et al. · Journal of Nuclear Medicine · 2011 · 67 citations · Full text

Medicine, Nuclear Medicine, Oncology +15

Delayed gadolinium-enhanced magnetic resonance imaging of cartilage (dGEMRIC), after slipped capital femoral epiphysis

Christoph Zilkens, Falk Miese, Bernd Bittersohl et al. · European Journal of Radiology · 2010 · 53 citations

Medicine, Orthopaedic Surgery, Radiology +14

Tumor Lesion Glycolysis and Tumor Lesion Proliferation for Response Prediction and Prognostic Differentiation in Patients With Advanced Non–Small Cell Lung Cancer Treated With Erlotinib

Deniz Kahraman, Arne Holstein, Matthias Scheffler et al. · Clinical Nuclear Medicine · 2012 · 48 citations

Medicine, Oncology, Pharmacology +17

Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib

Carsten Kobe, Matthias Scheffler, Arne Holstein et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2012 · 46 citations

Medicine, Nuclear Medicine, Oncology +16

Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib

Marc Bos, Masyar Gardizi, Hans‐Ulrich Schildhaus et al. · Lung Cancer · 2013 · 46 citations · Full text

Medicine, Molecular Genetics, Oncology +16